Provided by Tiger Trade Technology Pte. Ltd.

Karyopharm Therapeutics

1.61
-0.0100-0.62%
Post-market: 1.60-0.0096-0.60%19:59 EDT
Volume:6.74M
Turnover:9.67M
Market Cap:36.49M
PE:-0.12
High:1.61
Open:1.50
Low:1.24
Close:1.62
52wk High:10.99
52wk Low:1.24
Shares:22.66M
Float Shares:15.77M
Volume Ratio:8.47
T/O Rate:42.71%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-13.0816
EPS(LYR):-17.9300
ROE:-891.05%
ROA:-47.61%
PB:-0.11
PE(LYR):-0.09

Loading ...

Karyopharm Reports Second Quarter 2026 Financial Results and Highlights Continued Progress Toward Myelofibrosis Snda Submission

THOMSON REUTERS
·
Aug 13

Karyopharm Therapeutics Inc. Expected to Post a Loss of $1.28 a Share - Earnings Preview

Reuters
·
Aug 11

Karyopharm to Report Q2 2026 Results, Host Conference Call

Reuters
·
Aug 10

Karyopharm Therapeutics Inc. Expected to Post a Loss of $1.28 a Share - Earnings Preview

Reuters
·
Aug 08

Karyopharm Grants 333 RSUs to Newly Hired Employee Under Inducement Plan

Reuters
·
Aug 04

Karyopharm Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Aug 04

Top Midday Decliners

MT Newswires Live
·
Aug 01

Karyopharm price target lowered to $11 from $14 at Jefferies

TIPRANKS
·
Jul 31

Analysts Conflicted on These Healthcare Names: Karyopharm Therapeutics (KPTI), Baxter International (BAX) and Alnylam Pharma (ALNY)

TIPRANKS
·
Jul 31

Baird Downgrades Karyopharm Therapeutics to Neutral From Outperform, Adjusts Price Target to $3 From $15

MT Newswires Live
·
Jul 31

Karyopharm Therapeutics Cut to Neutral from Buy by HC Wainwright & Co.

Dow Jones
·
Jul 31

Karyopharm downgraded to Neutral from Buy at H.C. Wainwright

TIPRANKS
·
Jul 31

Karyopharm Therapeutics, Inc. : H.c. Wainwright Raises to Neutral from Buy

THOMSON REUTERS
·
Jul 31

Karyopharm downgraded to Neutral from Outperform at Baird

TIPRANKS
·
Jul 31

Premarket Movers | KPTI Plunged 67% as the XPORT-EC-042 Trial Failed to Hit Primary Endpoint

Tiger Newspress
·
Jul 31

Karyopharm Therapeutics Inc : Baird Cuts to Neutral Rating; Cuts Target Price to $3 from $15

THOMSON REUTERS
·
Jul 31

Karyopharm down 69% after XPORT-EC-042 trial did not meet primary endpoint

TIPRANKS
·
Jul 31

Karyopharm to submit sNDA for selinexor plus ruxolitinib

TIPRANKS
·
Jul 31

Karyopharm’s endometrial cancer candidate did not meet Phase 3 primary endpoint

TIPRANKS
·
Jul 31

Karyopharm trading resumes

TIPRANKS
·
Jul 31